Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/25247
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grech, Godfrey | - |
dc.contributor.author | Baldacchino, Shawn | - |
dc.contributor.author | Saliba, Christian | - |
dc.contributor.author | Fenech, Anthony G. | - |
dc.date.accessioned | 2018-01-02T11:12:05Z | - |
dc.date.available | 2018-01-02T11:12:05Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Grech, G., Baldacchino, S., Saliba, C., & Fenech, A. (2014). Predictive markers in cancer patient diagnosis, classification and prediction of therapy outcome using leukaemia as a model. Conference: EPMA World Congress 2013. In The Epma Journal 2014, (5, Suppl. 1): A26. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar//handle/123456789/25247 | - |
dc.description.abstract | The characterisation of the molecular mechanism of disease allows classification of patients into subtypes and potentially identifies specific targets for therapeutic intervention. Tyrosine kinase mutations are central to specific targeted therapy. Investigation of kinase deregulation within particular patient groups, has led to identification of mutant tyrosine kinases associated with disease progression and therapy modulation. Biomarker-specific therapies emerged, taking a leading role in guided-therapy. The extensive use of the specific kinase inhibitors and the longevity of the treatment protocols due to the uncertainty of residual disease, gave rise to new challenges, namely secondary resistance to therapy. Although there are various mechanisms of acquired resistance, mutations in the drug target itself play a dominant role. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Springer | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Protein-tyrosine kinase | en_GB |
dc.subject | Cancer -- Patients -- Treatment | en_GB |
dc.subject | Chronic myeloid leukemia | en_GB |
dc.subject | Acute myeloid leukemia | en_GB |
dc.title | Predictive markers in cancer patient diagnosis, classification and prediction of therapy outcome using leukaemia as a model | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.bibliographicCitation.conferencename | EPMA-World Congress 2013 | en_GB |
dc.bibliographicCitation.conferenceplace | Brussels, Belgium, 20-21/09/2013 | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1186/1878-5085-5-S1-A26 | - |
dc.publication.title | The EPMA Journal | en_GB |
Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Predictive markers in cancer patient diagnosis, classification and prediction of therapy outcome using leukaemia as a model.pdf | 151.24 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.